Wed, Aug 27, 2014, 9:35 AM EDT - U.S. Markets close in 6 hrs 25 mins

Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • wrb630 wrb630 Nov 3, 2011 7:19 PM Flag

    Many are Missing the Point

    This is a relatively New Company
    This is a Relatively New DRUG
    It was JUST Approved
    It saves lives
    Lt reduces Infections
    It reduce re-occurrences of infections

    Many Biotechs have no Approved Products
    Many Biotechs are borrowing everyday to stay Afloat

    There are many Large Pharmas that would love to add this product to their portfolio

    After a Full Quarter of Sales and more approvals in other regions of the world, the Upside is ENORMOUS

    This drug WORKS MUCH better than the competition...That is the most Important thing to consider

    Now Someone with any level of intelligence tell me anything negative

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Do not try to convince anybody it\s useless! Just stick to your shares and add at the dips.

      • 1 Reply to immunotecde
      • You are so right!!!!!!!!!! told Mike we would have a chance to add shares at low to mid $14'S..NEVER THOUGHT i WOULD SEE 13...BUT HERE IT IS!!! I plan to add big tmrw. I will wait to see if the uneducated take it lower.. I cannot believe that the shorts don't do DD...as this is very new and the numbers are good for such a promising drug....What idiot did not think there would be launch expenses?? Remember..,every day the need for this drug grows because of Vanco re-admissions...

    • I'd also say that the extra 6 cents per shate loss ( .57 over ..51) could easily be due to ramp up.

    • While I am long and have high hopes for optimer I still have to ask--
      IF big pharma wants to buy where are the offers. Trials are done,we have approval.

      Why would yell MUCH BETTER than the competition? Better yes but not tremendously so.

      Other than that I more or less agree.

      • 2 Replies to althomps48
      • offers tend to come during hard times, don't they, like when a stock has been pushed down after earnings without equivalent justification?

        If there's going to be a buy-out offer, it'll come this weekend (if OPTR is still down by 11%). If not then, it will not come.

      • Like the subject line says...missing the point....my mom contracted c-dif in the hospital...re-hospitalized 3 times....weakened her and created a Vancomycin resistance...she didnt recover enough after surgery...at least partially due to c-dif...took her to Hospice yesterday.....it's not a little better...it's quite a bit better...go to your local hospital and count the quarantine gown carts in the halls...now go to hospice and ask those affected if they wish that a drug thats better had been tried.....now...you get the point!!!!

    • This is a relatively New Company (yes and management and BOD and horrible)
      This is a Relatively New DRUG (yes, with no long-term composition of matter protection)
      It was JUST Approved (big deal, look at AMAG or DNDN for comparison of overbloated/hyped expectations)
      It saves lives (comprabable to oral Vanc)
      Lt reduces Infections (comprabable to oral Vanc)
      It reduce re-occurrences of infections (marginally, not worth the extra cost when generic Vanc makers hit the market...will be soon in the making!)

      Many Biotechs have no Approved Products (yes, but some do. Most have horrible management and cost/expense structures....OPTR has ~10VPs all making >$350K/year plus bonuses plus stock, which retail investors pay for)
      Many Biotechs are borrowing everyday to stay Afloat (yes, and this one will borrow as well as revenues can not keep up with expenses...rest assured there will be addtional offerings as well to dilute retail investors!)

      There are many Large Pharmas that would love to add this product to their portfolio (NOPE! Patent life not good enough. And best case scenario for commercial models are ~$200-250 Million/year...best case peak sales, but will never get there in my opinion)

      After a Full Quarter of Sales and more approvals in other regions of the world, the Upside is ENORMOUS (US will be there best market hands down, so added revenue from other markets are marginal)

      This drug WORKS MUCH better than the competition...That is the most Important thing to consider (NOPE, comprabable to Vanc, slight improvement in recurrence)

    • All those are good points but the street has spoken I (after hours). The stock is down 11%. Buy on rumor, sell on fact.

 
OPTR
12.78-0.15(-1.17%)Oct 23 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.